Symbols

Ovid Therapeutics Soars 12.73% on Penny Stock Hype

Generated by AI AgentAinvest Pre-Market Radar

Friday, Jul 18, 2025 9:10 am ET1min read

Aime Summary

- Ovid Therapeutics' stock surged 12.73% in pre-market trading on July 18, 2025, driven by penny stock hype and undervaluation in healthcare.

- The biopharma company gained attention as a top-performing penny stock, attracting investors seeking high-potential low-cost opportunities.

- Analysts highlighted its undervalued status, suggesting growth potential as market optimism anticipates future profitability and sector expansion.

Ovid Therapeutics' stock surged by 12.73% in pre-market trading on July 18, 2025, marking a significant rise for the biopharmaceutical company.

Ovid Therapeutics has been in the spotlight recently due to its inclusion in various lists of top-performing penny stocks. The company's stock has been noted for its substantial gains, attracting the attention of investors looking for high-potential, low-cost investments.

Analysts have highlighted the potential upside for Ovid TherapeuticsOVID--, citing its undervalued status in the healthcare sector. This positive outlook has contributed to the stock's recent surge, as investors anticipate future growth and profitability.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue